A/Prof. Laura Gray

The potential of baicalin to enhance neuroprotection and mitochondrial function in a human neuronal cell model

Z Liu, T Truong, C Bortolasci, B Spolding, B Panizzutti Parry, C Swinton, J Kim, D Hernández, S Kidnapillai, L Gray, M Berk, O Dean, K Walder

(2024), Molecular Psychiatry, Berlin, Germany, C1

Peri-Operative Risk Factors Associated with Post-Operative Cognitive Dysfunction (POCD): An Umbrella Review of Meta-Analyses of Observational Studies

N Travica, M Lotfaliany, A Marriott, S Safavynia, M Lane, L Gray, N Veronese, M Berk, D Skvarc, H Aslam, E Gamage, M Formica, K Bishop, W Marx

(2023), Vol. 12, Journal of Clinical Medicine, C1

Use of a gene expression signature to identify trimetazidine for repurposing to treat bipolar depression

C Bortolasci, S Kidnapillai, B Spolding, T Truong, T Connor, C Swinton, B Panizzutti, Z Liu, A Sanigorski, O Dean, T Crowley, M Richardson, K Bozaoglu, K Vlahos, S Cowdery, B Watmuff, S Steyn, D Wolmarans, B Engelbrecht, C Perry, K Drummond, T Pang, S Jamain, L Gray, S McGee, B Harvey, J Kim, M Leboyer, M Berk, K Walder

(2023), Vol. 25, pp. 661-670, Bipolar Disorders, C1

Minocycline as Treatment for Psychiatric and Neurological Conditions: A Systematic Review and Meta-Analysis

B Panizzutti, D Skvarc, S Lin, S Croce, A Meehan, C Bortolasci, W Marx, A Walker, K Hasebe, B Kavanagh, M Morris, M Mohebbi, A Turner, L Gray, L Berk, K Walder, M Berk, O Dean

(2023), Vol. 24, International Journal of Molecular Sciences, C1-1

Metergoline Shares Properties with Atypical Antipsychotic Drugs Identified by Gene Expression Signature Screen

C Bortolasci, E Jaehne, D Hernández, B Spolding, T Connor, B Panizzutti, O Dean, T Crowley, A Yung, L Gray, J Kim, M van den Buuse, M Berk, K Walder

(2023), Vol. 41, pp. 502-513, Neurotoxicity Research, C1

Effects of antipsychotic drugs on energy metabolism

B Panizzutti, C Bortolasci, B Spolding, S Kidnapillai, T Connor, S Martin, T Truong, Z Liu, L Gray, G Kowalski, S McGee, J Kim, M Berk, K Walder

(2023), European Archives of Psychiatry and Clinical Neuroscience, Germany, C1

Incorporation of patient and public involvement in statistical methodology research: development of an animation

H Worboys, J Broomfield, A Smith, R Stannard, F Tyrer, E Vounzoulaki, B Czyznikowska, G Grewal-Santini, J Greenwood, L Gray

(2023), Vol. 9, pp. 1-6, Research Involvement and Engagement, London, Eng., C1

Co-Expression Networks Unveiled Long Non-Coding RNAs as Molecular Targets of Drugs Used to Treat Bipolar Disorder

T Truong, C Bortolasci, B Spolding, B Panizzutti, Z Liu, S Kidnapillai, M Richardson, L Gray, C Smith, O Dean, J Kim, M Berk, K Walder

(2022), Vol. 13, Frontiers in Pharmacology, C1

Effects of Psychotropic Drugs on Ribosomal Genes and Protein Synthesis

Z Liu, T Truong, C Bortolasci, B Spolding, B Panizzutti, C Swinton, J Kim, S Kidnapillai, M Richardson, L Gray, O Dean, S McGee, M Berk, K Walder

(2022), Vol. 23, International Journal of Molecular Sciences, C1

Effects of psychoactive drugs on cellular bioenergetic pathways

C Bortolasci, B Spolding, S Kidnapillai, M Richardson, N Vasilijevic, S Martin, L Gray, S McGee, M Berk, K Walder

(2021), Vol. 22, pp. 79-93, World Journal of Biological Psychiatry, England, C1

Differential Level of RXFP3 Expression in Dopaminergic Neurons Within the Arcuate Nucleus, Dorsomedial Hypothalamus and Ventral Tegmental Area of RXFP3-Cre/tdTomato Mice

L Voglsanger, J Read, S Ch’ng, C Zhang, I Eraslan, L Gray, L Rivera, L Hamilton, R Williams, A Gundlach, C Smith

(2021), Vol. 14, Frontiers in Neuroscience, Switzerland, C1

Transcriptional modulation of the hippo signaling pathway by drugs used to treat bipolar disorder and schizophrenia

B Panizzutti, C Bortolasci, B Spolding, S Kidnapillai, T Connor, M Richardson, T Truong, Z Liu, G Morris, L Gray, J Kim, O Dean, M Berk, K Walder

(2021), Vol. 22, International Journal of Molecular Sciences, C1

Baseline serum amino acid levels predict treatment response to augmentation with N-acetylcysteine (NAC) in a bipolar disorder randomised trial

C Bortolasci, A Turner, M Mohebbi, Z Liu, M Ashton, L Gray, W Marx, A Walker, G Kowalski, F Jacka, M Berk, O Dean, K Walder

(2021), Vol. 142, pp. 376-383, Journal of Psychiatric Research, England, C1

Biological mechanism(S) underpinning the association between antipsychotic drugs and weight gain

B Panizzutti, C Bortolasci, B Spolding, S Kidnapillai, T Connor, M Richardson, T Truong, Z Liu, L Gray, J Kim, O Dean, M Berk, K Walder

(2021), Vol. 10, Journal of Clinical Medicine, C1

Exploring interleukin-6, lipopolysaccharide binding protein and brain-derived neurotrophic factor following 12 weeks of adjunctive minocycline treatment for depression

K Hasebe, M Mohebbi, L Gray, A Walker, C Bortolasci, A Turner, M Berk, K Walder, M Maes, B Kanchanatawan, M Ashton, L Berk, C Ng, G Malhi, A Singh, O Dean

(2021), Vol. 34, Acta Neuropsychiatrica, England, C1

The use of a gene expression signature and connectivity map to repurpose drugs for bipolar disorder

S Kidnapillai, C Bortolasci, M Udawela, B Panizzutti, B Spolding, T Connor, A Sanigorski, O Dean, T Crowley, S Jamain, L Gray, E Scarr, M Leboyer, B Dean, M Berk, K Walder

(2020), Vol. 21, pp. 775-783, World Journal of Biological Psychiatry, England, C1

Drugs used to treat bipolar disorder act via microRNAs to regulate expression of genes involved in neurite outgrowth

S Kidnapillai, B Wade, C Bortolasci, B Panizzutti, B Spolding, T Connor, T Crowley, S Jamain, L Gray, M Leboyer, M Berk, K Walder

(2020), Vol. 34, pp. 370-379, Journal of Psychopharmacology, United States, C1

Minocycline for the treatment of mental health and neurological conditions: study protocol of a systematic review and meta-analysis

C Bortolasci, W Marx, A Walker, K Hasebe, B Kavanagh, M Morris, M Mohebbi, A Turner, L Gray, L Berk, K Walder, M Berk, O Dean

(2020), Vol. 10, pp. e035080-, BMJ open, England, C1

Interleukin-6 and total antioxidant capacity levels following N-acetylcysteine and a combination nutraceutical intervention in a randomised controlled trial for bipolar disorder

C Bortolasci, C Voigt, A Turner, M Mohebbi, L Gray, S Dodd, K Walder, M Berk, S Cotton, G Malhi, C Ng, N Dowling, J Sarris, O Dean

(2020), Vol. 32, pp. 313-320, Acta Neuropsychiatrica, England, C1

Transcriptional effects of psychoactive drugs on genes involved in neurogenesis

C Bortolasci, B Spolding, S Kidnapillai, T Connor, T Truong, Z Liu, B Panizzutti, M Richardson, L Gray, M Berk, O Dean, K Walder

(2020), Vol. 21, pp. 1-19, International Journal of Molecular Sciences, C1

Phenotyping neurons activated in the mouse brain during restoration of salt debt

C Smith, J Cross, I Eraslan, A Attawar, S Ch'ng, P Dhar, R Samarasinghe, L Gray, A Lawrence

(2019), Vol. 101, Journal of Chemical Neuroanatomy, Netherlands, C1

Modulation of high fat diet-induced microbiome changes, but not behaviour, by minocycline

K Hasebe, L Rivera, C Smith, T Allnutt, T Crowley, T Nelson, O Dean, S McGee, K Walder, L Gray

(2019), Vol. 82, pp. 309-318, Brain, Behavior, and Immunity, Netherlands, C1

Drugs used in the treatment of bipolar disorder and their effects on cholesterol biosynthesis - a possible therapeutic mechanism

S Kidnapillai, C Bortolasci, B Panizzutti, B Spolding, T Connor, K Bonifacio, A Sanigorski, O Dean, T Crowley, S Jamain, L Gray, M Leboyer, M Berk, K Walder

(2019), Vol. 20, pp. 766-777, World Journal of Biological Psychiatry, London, Eng., C1

Post-operative cognitive dysfunction: an exploration of the inflammatory hypothesis and novel therapies

D Skvarc, M Berk, L Byrne, O Dean, S Dodd, M Lewis, A Marriott, E Moore, G Morris, R Page, L Gray

(2018), Vol. 84, pp. 116-133, Neuroscience and biobehavioral reviews, Amsterdam, The Netherlands, C1

Mechanisms underpinning the polypharmacy effects of medications in psychiatry

C Bortolasci, B Spolding, E Callaly, S Martin, B Panizzutti, S Kidnapillai, T Connor, K Hasebe, M Mohebbi, O Dean, S McGee, S Dodd, L Gray, M Berk, K Walder

(2018), Vol. 21, pp. 582-591, International Journal of Neuropsychopharmacology, England, C1

Mediator effects of parameters of inflammation and neurogenesis from a N-acetyl cysteine clinical-trial for bipolar depression

B Panizzutti, C Bortolasci, K Hasebe, S Kidnapillai, L Gray, K Walder, M Berk, M Mohebbi, S Dodd, C Gama, P Magalhães, S Cotton, F Kapczinski, A Bush, G Malhi, O Dean

(2018), Vol. 30, pp. 334-341, Acta Neuropsychiatrica, England, C1

Adjunctive N-acetylcysteine in depression: Exploration of interleukin-6, C-reactive protein and brain-derived neurotrophic factor

K Hasebe, L Gray, C Bortolasci, B Panizzutti, M Mohebbi, S Kidnapillai, B Spolding, K Walder, M Berk, G Malhi, S Dodd, O Dean

(2017), Vol. 29, pp. 337-346, Acta Neuropsychiatrica, England, C1

the effect of n-acetylcysteine (nac) on human cognition - a systematic review

D Skvarc, O Dean, L Byrne, L Gray, S Lane, M Lewis, B Fernandes, M Berk, A Marriott

(2017), Vol. 78, pp. 44-56, Neuroscience & Biobehavioral Reviews, Amsterdam, The Netherlands, C1

Affective dysfunction in a mouse model of Rett syndrome: therapeutic effects of environmental stimulation and physical activity

M Kondo, L Gray, G Pelka, S Leang, J Christodoulou, P Tam, A Hannan

(2016), Vol. 76, pp. 209-224, Developmental neurobiology, London, Eng., C1-1

N-acetylcysteine modulates glutamatergic dysfunction and depressive behavior in Huntington's disease

D Wright, L Gray, D Finkelstein, P Crouch, D Pow, T Pang, S Li, Z Smith, P Francis, T Renoir, A Hannan

(2016), Vol. 25, pp. 2923-2933, Human Molecular Genetics, England, C1

The Post-Anaesthesia N-acetylcysteine Cognitive Evaluation (PANACEA) trial: Study protocol for a randomised controlled trial

D Skvarc, O Dean, L Byrne, L Gray, K Ives, S Lane, M Lewis, C Osborne, R Page, D Stupart, A Turner, M Berk, A Marriott

(2016), Vol. 17, Trials, England, C1

N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease

D Wright, T Renoir, Z Smith, A Frazier, P Francis, D Thorburn, S McGee, A Hannan, L Gray

(2015), Vol. 5, pp. 1-10, Translational psychiatry, New York, N. Y., C1

Early life environmental and pharmacological stressors result in persistent dysregulations of the serotonergic system

P Wong, S Ying, L Gray, C Roei Chang, S Cai, X Zhang

(2015), Vol. 9, pp. 1-13, Frontiers in behavioral neuroscience, Lausanne, Switzerland, C1-1

Enhancing permanganate chemiluminescence detection for the determination of glutathione and glutathione disulfide in biological matrices

Z Smith, J Terry, N Barnett, L Gray, D Wright, P Francis

(2014), Vol. 139, pp. 2416-2422, Analyst, London, Eng., C1

Chronic adrenocorticotrophic hormone treatment alters tricyclic antidepressant efficacy and prefrontal monoamine tissue levels

A Walker, S Burnett, K Hasebe, J McGillivray, L Gray, S McGee, K Walder, M Berk, S Tye

(2013), Vol. 242, pp. 76-83, Behavioural brain research, Amsterdam, The Netherlands, C1

The promise of N-acetylcysteine in neuropsychiatry

M Berk, G Malhi, L Gray, O Dean

(2013), Vol. 34, pp. 167-177, Trends in pharmacological sciences, Oxford, England, C1

Mind and body: how the health of the body impacts on neuropsychiatry

T Renoir, K Hasebe, L Gray

(2013), Vol. 4, pp. 1-16, Frontiers in pharmacology, Lausanne, Switzerland, C1-1

Metabotropic glutamate receptors as targets for novel antipsychotic treatments.

L Gray, A Hannan, X Zhang

(2012), Vol. 13, pp. 1522-1534, Current pharmaceutical biotechnology, Amsterdam, The Netherlands, C1-1

Region and diagnosis-specific changes in synaptic proteins in schizophrenia and bipolar I disorder

L Gray, B Dean, H Kronsbein, P Robinson, E Scarr

(2010), Vol. 178, pp. 374-380, Psychiatry research, Amsterdam, The Netherlands, C1-1

Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-d-aspartic acid receptor up-regulation

L Gray, M van den Buuse, E Scarr, B Dean, A Hannan

(2009), Vol. 12, pp. 45-60, The international journal of neuropsychopharmacologyy, Oxford, Eng., C1

Sensitivity to MK-801 in phospholipase C-β1 knockout mice reveals a specific NMDA receptor deficit

L Gray, C McOmish, E Scarr, B Dean, A Hannan

(2009), Vol. 12, pp. 917-928, The international journal of neuropsychopharmacology, Oxford, England, C1-1

Role of muscarinic receptors in the activity of N-desmethylclozapine: reversal of hyperactivity in the phospholipase C knockout mouse

L Gray, C McOmish, E Scarr, B Dean, A Hannan

(2008), Vol. 19, pp. 543-547, Behavioural pharmacology, Philadelphia, Pa., C1-1

Environmental enrichment ameliorates a motor coordination deficit in a mouse model of Rett syndrome Mecp2 gene dosage effects and BDNF expression

M Kondo, L Gray, G Pelka, J Christodoulou, P Tam, A Hannan

(2008), Vol. 27, pp. 3342-3350, European journal of neuroscience, London, Eng., C1-1

Dissecting Cause and Effect in the Pathogenesis of Psychiatric Disorders: Genes, Environment and Behaviour

B Laura Gray, B Anthony J. Hannan

(2007), Vol. 7, pp. 470-478, Current Molecular Medicine, C1-1

Serotonin 1a receptor and associated G-protein activation in schizophrenia and bipolar disorder

L Gray, E Scarr, B Dean

(2006), Vol. 143, pp. 111-120, Psychiatry research, Amsterdam, The Netherlands, C1-1

Regionally specific changes in levels of cortical S100β in bipolar 1 disorder but not schizophrenia

B Dean, L Gray, E Scarr

(2006), Vol. 40, pp. 217-224, Australian and New Zealand journal of psychiatry, London, Eng., C1-1

N-Ethylmaleimide sensitive factor in the cortex of subjects with schizophrenia and bipolar I disorder

L Gray, E Scarr, B Dean

(2006), Vol. 391, pp. 112-115, Neuroscience letters, Amsterdam, The Netherlands, C1-1

Increased levels of SNAP-25 and synaptophysin in the dorsolateral prefrontal cortex in bipolar I disorder

E Scarr, L Gray, D Keriakous, P Robinson, B Dean

(2006), Vol. 8, pp. 133-143, Bipolar disorders, London, Eng., C1-1

A comparison of M1 and M4 muscarinic receptors in the thalamus from control subjects and subjects with schizophrenia

B Dean, L Gray, D Keriakous, E Scarr

(2004), Vol. 2, pp. 287-295, Thalamus & related systems, Amsterdam, The Netherlands, C1-1